Corium Announces Streamlined Bioequivalence Development Path for Transdermal Corplex^TM Donepezil Following Positive PreIND Communication from FDA
Reports Positive PK Results from Clinical Study of Optimized Once-weekly Corplex Donepezil for Alzheimer’s Disease MENLO PARK, Calif. , May 02, 2016 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture…